[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554086":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":38,"locations":47,"responsibleParty":75,"collaborators":25,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":25,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":25,"enrollmentInfo":88,"targetDuration":25,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":25,"overallStatus":68,"whyStopped":25,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"NALIRINOX combined with PD-1 synchronous sequential SBRT","EXPERIMENTAL","Nal-IRI+Oxaliplatin+5-FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, 6-8 cycles. SBRT is performed during the third cycle.",[13,14],"Drug: nal-IRI+Oxaliplatin+5-FU\u002FLV+PD-1","Drug: Gemcitabine + albumin-paclitaxel+PD-1",{"label":16,"type":10,"description":17,"interventionNames":18},"AG combined with PD-1 synchronous sequential SBRT","Gemcitabine + albumin-paclitaxel +PD-1, these drugs are given on d1, d8, 21 days as one cycle, 6-8 cycles. SBRT is performed during the third cycle.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","nal-IRI+Oxaliplatin+5-FU\u002FLV+PD-1","These drugs are given on d1, d15, 28 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.",[16,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Gemcitabine + albumin-paclitaxel+PD-1","These drugs are given on d1, d8, 21 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.",[16,9],[31,34],{"name":32,"affiliation":5,"role":33},"Juan Du","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":37},"Min Tu","The First Affiliated Hospital with Nanjing Medical University","STUDY_DIRECTOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":25,"email":43},"Juan Du, M.D. Ph.D","CONTACT","+86-025-83106666","dujunglyy@163.com",{"name":32,"role":41,"phone":45,"phoneExt":46,"email":43},"02583106666","+86",[48,67],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"FirstNanjingMU","NOT_YET_RECRUITING","Nanjing","Jiangsu","025","China","CN",{"type":57,"coordinates":58},"Point",[59,60],118.77778,32.06167,{"lat":60,"lon":59},[63,65],{"name":35,"role":41,"phone":64,"phoneExt":53,"email":25},"13585181045",{"name":35,"role":41,"phone":64,"phoneExt":53,"email":66},"tumin1215@163.com",{"facility":5,"status":68,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"RECRUITING",{"type":57,"coordinates":70},[59,60],{"lat":60,"lon":59},[73,74],{"name":40,"role":41,"phone":42,"phoneExt":25,"email":43},{"name":35,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":76,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Du Juan","chief physician choice","100554086","nalirifox-combined-with-pd-1-sequential-radiotherapy-versus-ag-combined-with-pd-1-sequential-radiotherapy-as-first-line-treatment-of-locally-advanced-pancreatic-cancer-100554086",false,"NCT06494514","NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer","A Single-center, Randomized, Interventional Controlled Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy for First-line Treatment of Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed pancreatic cancer;\n2. ECOG performance no more than 2;\n3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;\n4. No previous anti-tumor therapy；\n5. Able and willing to provide a written informed consent;\n\nExclusion Criteria:\n\n* 1\\. Prior anti-tumor therapy of any kind; 2. Severe infection (\\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.","ALL","18 Years",{"count":89,"type":90},40,"ESTIMATED","INTERVENTIONAL",[93],"NA","The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.",[96],"Locally Advanced Pancreatic Cancer","2024-07-02",{"date":99,"type":100},"2024-07-10","ACTUAL",{"date":102,"type":100},"2024-04-01",{"date":104,"type":90},"2027-04-01",{"name":77,"class":6},2]